ABEO Abeona Therapeutics Dashboard

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company's portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical needs. Abeona's novel, next-generation AIM™ capsids have shown potential to improve tropism profiles for a variety of devastating diseases. Abeona's fully functional, gene and cell therapy GMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and commercial production of AAV-based gene therapies.

Company profile

Ticker

ABEO

Exchange

NASDAQ

Website

abeonatherapeutics.com

CEO

Joao Siffert

Incorporated

Delaware

Location

New York

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Warner Chilcott ...

Former names

ACCESS PHARMACEUTICALS INC, CHEMEX PHARMACEUTICALS INC, PLASMATECH BIOPHARMACEUTICALS INC

SEC CIK

0000318306

Corporate docs

Articles of Incorporation & Bylaws

IRS number

830221517

ABEO stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Abeona Therapeutics Q2 EPS $(0.16) Down From $(0.14) YoY

28 Jul 21

Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.16) per share. This is a 14.29 percent decrease over losses of $(0.14) per share from the same period last year.

Abeona Stock Gains As It Concludes Type B Meeting With FDA For MPS IIIA Gene Therapy

28 Jul 21

Abeona Therapeutics Inc (NASDAQ: ABEO)

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

28 Jul 21

Abeona Therapeutics Reports Completed Type B Meeting With FDA For ABO-102 Gene Therapy In Sanfilippo Syndrome Type A

28 Jul 21

34 Stocks Moving in Tuesday's Pre-Market Session

27 Jul 21

Press releases

Pro users get this 30m faster

Abeona Therapeutics Reports Second Quarter Financial Results

28 Jul 21

Second clinical trial site activated in EB-101 pivotal Phase 3 VIITAL™ study Successful Type B meeting with U.S. FDA; Transpher A study will serve as the pivotal study for ABO-102 in MPS IIIA; Alignment with FDA

Thinking about buying stock in electroCore, General Electric, Gaotu Techedu, New Oriental Education, or Abeona Therapeutics?

28 Jul 21

NEW YORK, July 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ECOR, GE, GOTU, EDU, and ABEO.

Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA)

28 Jul 21

Transpher A; pivotal study for intended registration of ABO-102 for MPS IIIA disease Alignment with FDA on primary study endpoint NEW YORK and CLEVELAND, July 28, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc.

Thinking about buying stock in Xenetic Biosciences, Abeona Therapeutics, IMV Inc, Marathon Digital, or Riot Blockchain?

26 Jul 21

Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy

26 Jul 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

28 Jul 21

2 Aug 21

31 Dec 21

Financial summary

Financial statements Chart ABEO financial data

Quarter (USD)	Jun 21	Mar 21	Dec 20	Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	28.15M	28.15M	28.15M	28.15M	28.15M	28.15M
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	4.57M	4.09M	3.83M	3.12M
Cash used (since last report)	n/a	n/a	5.11M	4.57M	4.28M	3.48M
Cash remaining	n/a	n/a	23.04M	23.59M	23.87M	24.67M
Runway (months of cash)	n/a	n/a	5.0	5.8	6.2	7.9

Beta Read what these cash burn values mean

Recent insider trades

ABEO insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Jun 21	Vishwas Seshadri	Common stock	Grant	Aquire A	No	No	0	100,000	0	300,000
1 Jun 21	Vishwas Seshadri	Common stock	Grant	Aquire A	No	No	0	200,000	0	200,000
1 Jun 21	Vishwas Seshadri	Stock Option Common Stock	Grant	Aquire A	No	No	1.71	400,000	684K	400,000
25 May 21	Rouhandeh Steven H	Common Stock	Grant	Aquire A	No	No	0	38,590	0	533,590
25 May 21	Rouhandeh Steven H	Stock Option Common Stock	Grant	Aquire A	No	No	1.49	49,084	73.14K	49,084
25 May 21	Leila Alland	Common Stock	Grant	Aquire A	No	No	0	77,181	0	77,181
25 May 21	Leila Alland	Stock Option Common Stock	Grant	Aquire A	No	No	1.49	98,168	146.27K	98,168
25 May 21	Mark Alvino	Common Stock	Grant	Aquire A	No	No	0	77,181	0	82,181
25 May 21	Mark Alvino	Stock Option Common Stock	Grant	Aquire A	No	No	1.49	98,168	146.27K	98,168

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

ABEO institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	0
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Soligenix • Jazz Pharmaceuticals • Alder Biopharmaceuticals • Synedgen • Galera Therapeutics • uniQure • Regenxbio • Voyager Therapeutics • Editas Medicine • CRISPR Therapeutics

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: advocating, agreeing, alleviate, argued, assign, ATM, authorizing, behalf, binding, card, choose, confidential, conflict, creation, credit, diligence, embodying, extinguishment, factor, foregoing, hand, injunction, invalidity, invention, inventorship, joint, July, launch, law, lowest, minimum, notice, permanent, permit, prevent, priority, relevant, settlement, valid, yearly

Removed: assessment, capability, consistent, detail, entity, legal, measuring, obtained, professional, QUALITATIVE, QUANTITATIVE, refer

From filing 10-Q 2021 Q2